These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Impact of doxycycline on Clostridioides difficile infection in patients hospitalized with community-acquired pneumonia. O'Leary AL; Chan AK; Wattengel BA; Xu J; Mergenhagen KA Am J Infect Control; 2024 Mar; 52(3):280-283. PubMed ID: 37921728 [TBL] [Abstract][Full Text] [Related]
5. Observational study in a single institute in Japan: How many community-onset pneumonia patients would have Clostridioides difficile infections after treatment? Asai N; Sakanashi D; Suematsu H; Kato H; Shiota A; Hagihara M; Koizumi Y; Yamagishi Y; Mikamo H J Infect Chemother; 2020 Oct; 26(10):1104-1106. PubMed ID: 32713744 [TBL] [Abstract][Full Text] [Related]
6. Association Between Antibiotic Use and Hospital-onset Clostridioides difficile Infection in US Acute Care Hospitals, 2006-2012: An Ecologic Analysis. Kazakova SV; Baggs J; McDonald LC; Yi SH; Hatfield KM; Guh A; Reddy SC; Jernigan JA Clin Infect Dis; 2020 Jan; 70(1):11-18. PubMed ID: 30820545 [TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone-associated adverse events of interest among hospitalized veterans affairs patients with community-acquired pneumonia who were treated with a fluoroquinolone: A focus on tendonitis, Clostridioides difficile infection, and aortic aneurysm. Patel N; Gorseth A; Belfiore G; Stornelli N; Lowry C; Thomas L Pharmacotherapy; 2024 Jan; 44(1):49-60. PubMed ID: 37699580 [TBL] [Abstract][Full Text] [Related]
8. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913 [TBL] [Abstract][Full Text] [Related]
10. Association of antibiotic use and acute kidney injury in patients hospitalized with community-acquired pneumonia. Le P; Navaneethan SD; Yu PC; Pallotta AM; Rastogi R; Patel P; Brateanu A; Imrey PB; Rothberg MB Curr Med Res Opin; 2022 Mar; 38(3):443-450. PubMed ID: 34714213 [TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027. Wieczorkiewicz JT; Lopansri BK; Cheknis A; Osmolski JR; Hecht DW; Gerding DN; Johnson S Antimicrob Agents Chemother; 2016 Jan; 60(1):418-23. PubMed ID: 26525793 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection. Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789 [No Abstract] [Full Text] [Related]
13. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787 [TBL] [Abstract][Full Text] [Related]
14. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. Chalmers JD; Akram AR; Singanayagam A; Wilcox MH; Hill AT J Infect; 2016 Jul; 73(1):45-53. PubMed ID: 27105657 [TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Raz-Pasteur A; Shasha D; Paul M Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096 [TBL] [Abstract][Full Text] [Related]
18. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Incidence Rate of Healthcare-Associated Clostridium difficile Infection: A Non-Randomized, Stepped Wedge, Single-Site, Observational Study. DiDiodato G; McArthur L PLoS One; 2016; 11(6):e0157671. PubMed ID: 27309536 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Dudas V; Hopefl A; Jacobs R; Guglielmo BJ Ann Pharmacother; 2000 Apr; 34(4):446-52. PubMed ID: 10772428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]